BEVERLY, Mass., July 14, 2009 (GLOBE NEWSWIRE) -- Cellceutix Corporation (OTCBB:CTIX) announced today that Dr. Samuel Danishefsky has agreed to serve on the Cellceutix Scientific Advisory Board through July 6, 2010.
Dr. Danishefsky stated, "I am pleased to have the opportunity to work with a dynamic young company like Cellceutix. I am very encouraged that the company's lead chemotherapy compound, Kevetrin(tm), has shown activity in animal models of drug resistant lung cancers. Lung cancer causes more deaths annually in Western countries than breast, colorectal and prostate cancers combined. I look forward to contributing to the development of Kevetrin and other Cellceutix compounds."
Krishna Menon, President and Chief Scientific Officer, stated, "Dr. Danishefsky is one of the most well-respected chemists in the world, having made many significant contributions in the field of cancer research. Having him join our Scientific Advisory Board will help us immensely in our compound development research efforts. He will be an excellent fit for our Board."
Dr. Danishefsky is an internationally recognized leader in chemistry, specializing in the synthesis of biologically active organic compounds. Dr. Danishefsky earned his Ph.D. in chemistry from Harvard. He spent 14 years at Yale University, where he rose to the rank of Sterling Professor of Chemistry, the highest academic rank at Yale University, awarded to a tenured faculty member considered one of the best in his or her field. By 1991, he was also sharing his time with Memorial Sloan-Kettering Cancer Center as director of the Laboratory for Cancer Research Bioorganic Chemistry, becoming chair in 1993. He accepted an appointment as professor at Columbia University in 1993, and now conducts research at both institutions.
AWARDS
Shared the distinguished Wolf Award and $100,000 Prize, with Gilbert Stork American Chemical Society's Guenther Award Aldrich Award for Creative Work in Synthetic Organic Chemistry Benjamin Franklin Medal in Chemistry National Academy of Sciences' NAS Award in Chemical Sciences Cope Medal -- American Chemical Society And numerous other awards.
About Cellceutix
Cellceutix is a preclinical cancer and anti-inflammatory drug developer. It owns the rights to six drug compounds, including Kevetrin, which it is developing as a treatment for certain cancers, and KM-133, which it is developing for psoriasis. This Press Release contains forward-looking statements that are based on our current expectations, beliefs and assumptions. Actual results may differ materially from what is expressed in these statements, and no assurance can be given that Cellceutix can successfully implement its core business strategy and improve future earnings. All forward-looking statements are also expressly qualified in their entirety by the cautionary statements included in our SEC filings, including our quarterly reports on Form 1O-Q and annual report on Form 10-K.
The Cellceutix Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6397
This Press Release contains forward-looking statements that are based on our current expectations, beliefs and assumptions. Actual results may differ materially from what is expressed in these statements, and no assurance can be given that Cellceutix can successfully implement its core business strategy and improve future earnings.
All forward-looking statements are also expressly qualified in their entirety by the cautionary statements included in our SEC filings, including our quarterly reports on Form 1O-Q and annual report on Form 10-K.